FIELD: medicine; pharmacology.
SUBSTANCE: CCI-779 cosolvent concentrate includes 0.05 to 50 mg/ml of CCI-779, alcohol solvent and 0.001 to 1.0 wt % per volume of antioxidant component. Invention also claims parenteral composition including the described concentrate and method of its obtainment.
EFFECT: improved storage and dissolution stability of the concentrate.
25 cl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
LYOPHILISED COMPOSITIONS CCI-779 | 2004 |
|
RU2345772C2 |
CCI-779 FOR AMPHICYTE LYMPHOMA TREATMENT | 2004 |
|
RU2358731C2 |
ANTI-TUMOR COMPOSITIONS CONTAINING RAPAMICINE DERIVATIVE AND AROMATASE INHIBITOR | 2004 |
|
RU2355399C2 |
ORAL COMPOSITIONS | 2003 |
|
RU2326654C2 |
PROPOFOL DELIVERY SYSTEMS | 2016 |
|
RU2709812C2 |
PHARMACEUTICAL COMPOSITION | 2005 |
|
RU2320365C2 |
EPOTHILONE-CONTAINING COMPOSITIONS | 1999 |
|
RU2214246C2 |
LYOPHILIZED COMPOSITION | 1999 |
|
RU2268045C2 |
FOOD EMULSIONS | 2011 |
|
RU2580470C2 |
ANTICANCER PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATING BREAST CANCER | 2015 |
|
RU2581022C1 |
Authors
Dates
2009-01-27—Published
2003-07-25—Filed